Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

by Dent, R.A, Lindeman, G.J, Clemons, M, Wildiers, H, Chan, A, McCarthy, N.J, Singer, C.F, Lowe, E.S, Watkins, C.L, Carmichael, J
Published 2020

Retroviral insertional mutagenesis implicates E3 ubiquitin ligase RNF168 in the control of cell proliferation and survival

by Kizilors A., Pickard M.R., Schulte C.E., Yacqub-Usman K., McCarthy N.J., Gan S.-U., Darling D., G鋕en J., Williams G.T., Farzaneh F.
Published 2018